Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated chemoradiation followed by durvalumab for unresectable locally advanced non-small cell lung cancer
ACTRN12620001198910Phase 2Active, not recruiting
- Sponsor
- Calvary Mater Newcastle
- Start
- Apr 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, paclitaxel and carboplatin in non-small cell lung cancer (NSCLC), sponsored by Calvary Mater Newcastle. Primary endpoint: Safety. Started Apr 2021; status: active, not recruiting.
02
Drugs
durvalumabpaclitaxelcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ACTRN12620001198910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001198910.